The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control
Services
Services
Date issued
2014Journal title
Haematologica
Type of content
Publicación de congreso
